TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 39422598
Drug: Fianlimab monotherapy
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fianlimab monotherapy (exact dosage not specified)
Study: 39422598
Drug: Transition from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transition from fianlimab monotherapy to combination therapy
Study: 39422598
Drug: Fianlimab pharmacokinetics
Normalized name: Fianlimab
DrugBank: Fianlimab (DB18858)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fianlimab pharmacokinetics
Study: 39422598
Drug: Fianlimab 1,600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fianlimab 1,600 mg Q3W (20 mg/kg in an 80-kg individual)
Study: 39422604
Drug: FAP-IL2v (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: FAP-IL2v (10 mg, QW/Q2W) in combination with cetuximab (500 mg/m2, Q2W)
Study: 39422741
Drug: Eribulin 1.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eribulin 1.4 mg/m2 administered as a single dose after tumor removal.
Study: 39422764
Drug: Tislelizumab plus
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab plus low-dose bevacizumab
Study: 39422837
Drug: 0.1% loading
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% loading dose for 6 months followed by 0.01% for 18 months
Study: 39422960
Drug: Nerve growth
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve growth factor (NGF) gene therapy
Study: 39423355
Drug: Atezolizumab (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atezolizumab (1,200 mg) plus Bevacizumab (15 mg/kg)
Study: 39424007
Drug: Cold snare
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold snare resection in aspirin users
Study: 39424467
Drug: Extended antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended antibiotics
Study: 39424467
Drug: Standard antibiotics
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antibiotics
Study: 39424513
Drug: Osimertinib 80
Normalized name: osimertinib 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib 80 mg once daily plus bevacizumab 15 mg/kg every 3 weeks
Study: 39424513
Drug: Osimertinib monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Osimertinib monotherapy 80 mg once daily
Study: 39424559
Drug: Combination Therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination Therapy (CBT + Modafinil)
Study: 39424560
Drug: Fasudil 30
Normalized name: fasudil
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil 30 mg (15 mg twice daily)
Study: 39424560
Drug: Fasudil 60
Normalized name: fasudil
DrugBank: Fasudil (DB08162)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Fasudil 60 mg (30 mg twice daily)
Study: 39424598
Drug: 1 mg
Normalized name: biotin 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mg once-weekly subcutaneous semaglutide (GLP-1 RA)
Study: 39424742
Drug: Adjunctive brexpiprazole
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjunctive brexpiprazole 2 mg/day
Study: 39424775
Drug: Oliceridine (2-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oliceridine (2-20 μg/kg/h)
Study: 39424775
Drug: Remifentanil (1.5-12
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil (1.5-12 μg/kg/h)
Study: 39425028
Drug: Pyrotinib 400
Normalized name: Pyrotinib
DrugBank: Pyrotinib (DB14993)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pyrotinib 400 mg per day and metronomic oral etoposide 50 mg per day d1-21 every 28 days
Study: 39425032
Drug: TELESCOPE intervention:
Approvals — FDA: no, EMA: no, PMDA: no
Description: TELESCOPE intervention: telehealth decision coaching and navigation session about LCS delivered by trained patient navigators, with a low-dose CT scan (LDCT) order placed for each patient wanting LCS.
Study: 39425170
Drug: Multifaceted antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multifaceted antibiotic stewardship intervention (ASI) including a decision-tool and toolbox, implemented with educational and evaluation sessions.
Study: 39425234
Drug: Tranexamic acid
Normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Tranexamic acid (loading dose 1000 mg over 10 min prior to skin incision, maintenance dose 125 mg/h until skin closure or until 1000 mg administered)
Study: 39425245
Drug: 5-mL injection
Normalized name: carbamazepine
DrugBank: Carbamazepine (DB00564)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5-mL injection of autologous conditioned plasma after arthroscopic partial meniscectomy
Study: 39425927
Drug: Hyperbaric oxygen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyperbaric oxygen therapy (HBO) - 30 procedures, 60 min inhalation of pure oxygen at 2.5 atm, 5 days a week
Study: 39425927
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - 29 healthy male volunteers aged 25-69 years, no HBO therapy previously
Study: 39426385
Drug: Cadonilimab (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cadonilimab (10 mg/kg) plus platinum-based chemotherapy with or without bevacizumab
Study: 39426385
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus platinum-based chemotherapy with or without bevacizumab
Study: 39426393
Drug: Lomitapide (starting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lomitapide (starting at 2 mg for ages 5-15 years or 5 mg for ages 16-17 years)
Study: 39426785
Drug: 200-mg vaginal
Normalized name: clotrimazole
DrugBank: Clotrimazole (DB00257)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 200-mg vaginal progesterone daily
Study: 39426836
Drug: GMRx2 (telmisartan
Approvals — FDA: no, EMA: no, PMDA: no
Description: GMRx2 (telmisartan 20 mg, amlodipine 2·5 mg, indapamide 1·25 mg)
Study: 39426836
Drug: Telmisartan-indapamide (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan-indapamide (20 mg telmisartan, 1·25 mg indapamide)
Study: 39426836
Drug: Telmisartan-amlodipine (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan-amlodipine (20 mg telmisartan, 2·5 mg amlodipine)
Study: 39426836
Drug: Amlodipine-indapamide (2·5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine-indapamide (2·5 mg amlodipine, 1·25 mg indapamide)
Study: 39427182
Drug: Micro-fragmented adipose
Normalized name: human adipose preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Micro-fragmented adipose tissue injection (stem cell treatment)
Study: 39427187
Drug: CHF6523 inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHF6523 inhaled twice daily for 28 days
Study: 39427187
Drug: Placebo inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaled twice daily for 28 days
Study: 39427441
Drug: COMBO450 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMBO450 plus pembrolizumab (binimetinib 45 mg twice daily, pembrolizumab 200 mg every 3 weeks, encorafenib 450 mg once daily)
Study: 39427441
Drug: COMBO300 plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: COMBO300 plus pembrolizumab (binimetinib 45 mg twice daily, pembrolizumab 200 mg every 3 weeks, encorafenib 300 mg once daily)
Study: 39428126
Drug: Perioperative nivolumab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Perioperative nivolumab plus chemotherapy (ChIO)
Study: 39428453
Drug: HEIS Proximal
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: HEIS Proximal Daily Activity Limitations (PDAL) score
Study: 39428688
Drug: Methotrexate and
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate and cytarabine (Ara-C) therapy every 35 days for six cycles
Study: 39429509
Drug: Food Frequency
Normalized name: ALLERGENIC EXTRACT, FOOD, WHEAT
DrugBank: Wheat (DB10579)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Food Frequency Questionnaire (FFQ) administered at baseline and after 3 weeks
Study: 39430399
Drug: Myofascial Trigger
Normalized name: Anti-AML/SCCL-trigger monoclonal antibody
DrugBank: pM-81 (DB17432)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Myofascial Trigger Point Therapy (MPT)
Study: 39430462
Drug: Evolocumab (PCSK9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Evolocumab (PCSK9 inhibitor) in addition to high-intensity statin therapy for 12 weeks
Study: 39430462
Drug: Placebo in
Normalized name: placebo INTRAVEN VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo in addition to high-intensity statin therapy for 12 weeks
Study: 39430683
Drug: Novel analgesics
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel analgesics (mechanisms) evaluated in the study design.
Study: 39431459
Drug: Lower starting
Normalized name: flowers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lower starting dose of CDK4/6 inhibitors combined with endocrine therapy
Study: 39431459
Drug: Full dose
Normalized name: BayRHo-D Full Dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Full dose of CDK4/6 inhibitors combined with endocrine therapy
Study: 39431909
Drug: Multimodal treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal treatment for ADHD, details on dosage and duration not available.
Study: 39432161
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg PO daily
Study: 39432177
Drug: Convalescent plasma
Normalized name: Convalescent plasma
DrugBank: COVID-19 convalescent plasma (DB15692)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Convalescent plasma (CP) treatment
Study: 39432252
Drug: Crushed ticagrelor
Normalized name: Ticagrelor
DrugBank: Ticagrelor (DB08816)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Crushed ticagrelor (180 mg loading dose)
Study: 39432292
Drug: Primary care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary care and school interventions (various programs including Yes We Can Children's Asthma Program, Open Airways For Schools Plus, and school-based asthma therapy).
Study: 39432296
Drug: 3 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 cycles of CEV chemotherapy
Study: 39432296
Drug: 6 cycles
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 cycles of CEV chemotherapy
Study: 39432457
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D supplementation (4,000 IU capsule daily)
Study: 39432509
Drug: Bedaquiline 800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bedaquiline 800 mg with rifampicin 600 mg (BE-PEP)
Study: 39432509
Drug: Rifampicin 600
Normalized name: Rifampicin 600 mg powder for solution for infusion vial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 600 mg alone (SDR-PEP)
Study: 39432745
Drug: CBG-002 therapy
Normalized name: camphor 0.002 MG/MG / menthol 0.035 MG/MG [Bioease Pain Relieving Cold Therapy]
Approvals — FDA: no, EMA: no, PMDA: no
Description: CBG-002 therapy
Study: 39432867
Drug: DKN-01 300
Normalized name: Dkk1-neutralizing monoclonal antibody dkn-01
DrugBank: Sirexatamab (DB17515)
Approvals — FDA: no, EMA: no, PMDA: no
Description: DKN-01 300 mg once every 2 weeks, tislelizumab 200 mg once every 3 weeks, oxaliplatin 130 mg/m2
Study: 39433132
Drug: Selective serotonin
Normalized name: Selective serotonin (5HT1) agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective serotonin reuptake inhibitors (SSRIs) treatment for 8 weeks
Study: 39434114
Drug: Fisetin (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fisetin (single oral dose of 20 mg/kg)
Study: 39434114
Drug: Fisetin (two
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fisetin (two oral doses of 20 mg/kg each spaced 1 day apart)
Study: 39434160
Drug: Time-restricted eating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Time-restricted eating (16:8) combined with training program (combination group, n=28)
Study: 39434179
Drug: Cognitive rehabilitation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive rehabilitation programme (ten 1-hour sessions, delivered weekly)
Study: 39434191
Drug: Lactated Ringer's
Normalized name: LACTATED RINGER'S
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactated Ringer's solution (LR) for fluid resuscitation for at least 48 hours
Study: 39434431
Drug: Cofrogliptin 10
Normalized name: Gosogliptin
DrugBank: Gosogliptin (DB08382)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cofrogliptin 10 mg
Study: 39434431
Drug: Cofrogliptin 25
Normalized name: Gosogliptin
DrugBank: Gosogliptin (DB08382)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cofrogliptin 25 mg
Study: 39434634
Drug: Tegoprazan-containing sequential
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tegoprazan-containing sequential therapy
Study: 39434634
Drug: Esomeprazole-containing sequential
Approvals — FDA: no, EMA: no, PMDA: no
Description: Esomeprazole-containing sequential therapy
Study: 39434728
Drug: Conventional antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional antibiotic irrigation (rifampin 600 mg/L of sterile water, gentamicin 80 mg/L of sterile water)
Study: 39435124
Drug: Feel-Good inpatient
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Feel-Good inpatient therapy group
Study: 39435387
Drug: AquOTic intervention
Normalized name: hydroquinone
DrugBank: Hydroquinone (DB09526)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AquOTic intervention (10-week occupational therapy-based aquatic intervention)
Study: 39435713
Drug: Intravenous tenecteplase
Normalized name: Tenecteplase
DrugBank: Tenecteplase (DB00031)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous tenecteplase plus endovascular thrombectomy
Study: 39435908
Drug: 1.0 or
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.0 or 2.5 mg parsaclisib orally once daily for 12 weeks
Study: 39436270
Drug: Graded motor
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Graded motor imagery plus multimodal physical therapy
Study: 39436476
Drug: Elevated Systemic
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated Systemic Immune-Inflammation Index (SII) > 0.437 in patients on clopidogrel plus aspirin therapy
Study: 39436588
Drug: Mean Heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean Heart Dose (MHD) for patients with no subclinical damage
Study: 39436588
Drug: Mean Heart
Normalized name: porcine heart preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean Heart Dose (MHD) for patients with subclinical heart damage
Study: 39436684
Drug: FACET home
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: FACET home monitoring system along with standard treatment
Study: 39436905
Drug: Investigational hand
Approvals — FDA: no, EMA: no, PMDA: no
Description: Investigational hand therapy intervention
Study: 39436905
Drug: Traditional occupational
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional occupational therapy approach
Study: 39436955
Drug: Triple therapy
Normalized name: MigreLief Triple Therapy with Puracol Caplet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple therapy for COPD
Study: 39437217
Drug: Metformin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metformin (500 mg 3× per day for 20 days before and 10 days after surgery)
Study: 39437546
Drug: Venetoclax (Ven)
DrugBank: Venetoclax (DB11581)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Venetoclax (Ven) 400 mg daily with biweekly Pegcrisantaspase (PegC) 750 IU/m2
Study: 39437708
Drug: zanubrutinib 160mg
Normalized name: Zanubrutinib
DrugBank: Zanubrutinib (DB15035)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: zanubrutinib 160mg twice daily and obinutuzumab 1000mg on cycle 1 day 1, 8, 15 and day 1 of cycles 2-8, followed by venetoclax with weekly dose-ramp up to 400mg daily after 2 cycles
Study: 39437815
Drug: Gas chromatography-ion
Normalized name: Sulfate ion
DrugBank: Sulfate ion (DB14546)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gas chromatography-ion mobility spectrometry (GC-IMS) analysis of volatile organic compounds (VOCs) in exhaled breath, blood, and urine.
Study: 39438096
Drug: DMX-200 120 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMX-200 120 mg two times per day on background of titratable candesartan commencing at 4 mg two times per day for 28 days.
Study: 39438096
Drug: Placebo on
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo on background of titratable candesartan commencing at 4 mg two times per day for 28 days.
Study: 39438108
Drug: Resuming DOAC
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resuming DOAC at standard dosing starting at 30 days (30+7)
Study: 39438108
Drug: Resuming DOAC
Normalized name: omega-3 acid ethyl esters (USP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Resuming DOAC at standard dosing starting at 90 days (90±14)
Study: 39438126
Drug: Bisacodyl 10
Normalized name: bisacodyl 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bisacodyl 10 mg daily for 10 days
Study: 39438126
Drug: Hyoscine 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hyoscine 20 mg three times per day for 10 days
Study: 39438467
Drug: Ruxolitinib (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ruxolitinib (5 mg/day) combined with methylprednisolone (1 mg/kg/day)
Study: 39438467
Drug: Methylprednisolone alone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone alone (2 mg/kg/day)
Study: 39438621
Drug: Random Forest
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random Forest (RF) ML model in internal validation cohort
Study: 39438621
Drug: Random Forest
Normalized name: jojoba oil, randomized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Random Forest (RF) ML model in temporal validation cohort
Study: 39438942
Drug: Ertugliflozin (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ertugliflozin (5 mg once daily)
Study: 39439007
Drug: 7 ml/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 ml/kg Ringer's Lactate infusion over 10 min
Study: 39439041
Drug: Hybrid telemental
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid telemental health (TMH) treatment
Study: 39439041
Drug: Hybrid TMH
Normalized name: Amaranthus hybridus pollen
DrugBank: Amaranthus hybridus pollen (DB15503)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hybrid TMH treatment
Study: 39440042
Drug: Intensified trans-sectoral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensified trans-sectoral nutritional intervention for 6 months (face-to-face dietary counseling, oral nutritional supplementation, telephone-based nutrition and exercise coaching)
Study: 39440409
Drug: 25 μg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg oral solution of misoprostol
Study: 39440409
Drug: 25 μg oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 μg oral tablet of misoprostol
Study: 39440428
Drug: Left bundle-optimized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Left bundle-optimized therapy CRT (LOT-CRT)
Study: 39440720
Drug: PRO-CTCAE administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: PRO-CTCAE administration and reporting recommendations
Study: 39441230
Drug: Higher 24-h
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher 24-h urinary iodine excretion (24-h UIE)
Study: 39441483
Drug: Stereotactic radiotherapy
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Stereotactic radiotherapy (SRT) 4 × 8 Gy and sequential nivolumab administration until disease progression or unacceptable toxicity
Study: 39441519
Drug: Ritlecitinib 10-200/50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib 10-200/50 mg
Study: 39441519
Drug: Ritlecitinib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ritlecitinib (all doses)
Study: 39441591
Drug: Pregabalin (50-300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pregabalin (50-300 mg/d)
Study: 39441642
Drug: Blended cognitive
Normalized name: Io-Blend
Approvals — FDA: no, EMA: no, PMDA: no
Description: Blended cognitive behavioral therapy (bCBT) combining internet-based cognitive behavioral therapy (iCBT) and face-to-face cognitive behavioral therapy (FtF CBT)
Study: 39441642
Drug: Face-to-face cognitive
Normalized name: FACE SHIELD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Face-to-face cognitive behavioral therapy (FtF CBT)
Study: 39441873
Drug: Home-based self-treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Home-based self-treatment program (muscle-stretching and active mobilization exercises for 40'/day for 6 weeks)
Study: 39442013
Drug: Lebrikizumab 250
Normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 250 mg Q2W or Q4W combined with topical corticosteroids (TCS) in the maintenance primary population (MPP)
Study: 39442013
Drug: Lebrikizumab 250
Normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 250 mg Q2W with TCS in the maintenance escape population (MEP)
Study: 39442013
Drug: Lebrikizumab 250
Normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 250 mg Q2W or Q4W combined with TCS in the MPP
Study: 39442013
Drug: Lebrikizumab 250
Normalized name: Lebrikizumab 250 mg in 2 mL SUBCUTANEOUS INJECTION, SOLUTION [EBGLYSS]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lebrikizumab 250 mg Q2W with TCS in the MEP
Study: 39442326
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment (diaphragmatic plication)
Study: 39442326
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (clinical follow-up)
Study: 39442386
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Jaktinib administered orally on day 1 in mild hepatic impairment group (n=8)
Study: 39442386
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Jaktinib administered orally on day 1 in moderate hepatic impairment group (n=8)
Study: 39442386
Drug: 100 mg
Normalized name: urea 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 mg Jaktinib administered orally on day 1 in normal hepatic function group (n=8)
Study: 39442667
Drug: STAND (Motivational
Approvals — FDA: no, EMA: no, PMDA: no
Description: STAND (Motivational Interviewing-Enhanced Behavior Therapy)
Study: 39442958
Drug: Intensive adjuvant
Normalized name: Uricalm Intensive
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive adjuvant treatment (arm A): four cycles of docetaxel, epirubicin, and cyclophosphamide followed by four cycles of gemcitabine and cisplatin (n=166)